Catalyst Wire Dossier Catalyst Wire Dossier

CAR-T cells targeting CD19 and CD20

anti-CD19 and anti-CD20 chimeric antigen receptor T cells · National Cancer Institute (sponsor)
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CAR-T cells targeting CD19 and CD20, covering 2022-02-15 to 2022-02-15. Get the full timeline:

Most recent: Clinical Trial Update: T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma [Phase 1]

See pricing